Ascend Laboratories LLC
$60.0K 12 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
SRS Medical Systems, Inc.
SRS Medical Systems, Inc. reported $60,091.96 across General Payments, Research, and Ownership to 187 physicians and teaching hospitals across 192 transactions.
- $60.1K
- All-tracks total
- 192
- Transactions
- 187
- Recipients
- +$8.4K
- General Payments vs PY2023
SRS Medical Systems, Inc. reported $60,091.96 across all CMS Open Payments tracks (General + Research + Ownership) to 187 physicians and teaching hospitals in Program Year 2024 - ranking #1310 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $54,605.47, averaging $321.35 per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer srs-medical-systems-inc SRS Medical Systems, Inc.
$60.1K · #1310/1,925 · 0.0% industry · PY2024
- TOT $60.1K
- RANK #1310
- SHARE 0.0%
- TXN 192
- RCP 187
- CAT 2
- GEN $54.6K
- ΔGEN +$8.4K
- TOP1 41.2%
- PY 2024
Volume peers
Nearest volume peer: Ascend Laboratories LLC ($60.0K)
SRS Medical Systems, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
SRS Medical Systems, Inc.'s CMS-reported General Payments increased by $8.4K (+18.1%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: SRS MEDICAL SYSTEMS, INC.PY2023: SRS MEDICAL SYSTEMS, INC.PY2024: SRS Medical Systems, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $46,221.28
- PY2024
- $54,605.47
What the Data Shows for SRS Medical Systems, Inc.
Averaging $312.98 per transaction and $321.35 per recipient, SRS Medical Systems, Inc.'s Program Year 2024 total comes to $60,091.96 across 192 transactions and 187 physicians and teaching hospitals. In the CMS Open Payments database that is good for rank #1310 of 1,925 companies, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.
Of the 2 general-payment categories charted below, "Consulting Fee" is the largest at $43.3K across 26 transactions, 79.2% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Consulting Fee" leads SRS Medical Systems, Inc.'s 2-category general-payment breakdown at $43.3K, 79.2% of the reported total.
How SRS Medical Systems, Inc. divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $43.3K | 26 | 79.2% |
| Food and Beverage | $11.4K | 161 | 20.8% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $43,640.20 (79.9%) of $54,605.47 in this company's General Payments records across 160 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for SRS Medical Systems, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Kevin Mcvary
$22,500.00 across 12 reported transactions
- 2
Douglas Swartz
$18,000.00 across 12 reported transactions
- 3
Janelle Bunce
$2,500.00 across 1 reported transactions
- 4
Lewis Kriteman
$390.20 across 3 reported transactions
- 5
Angelo Cambio
$250.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as SRS Medical Systems, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about SRS Medical Systems, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with SRS Medical Systems, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
NDLX Health Sciences, LLC
$60.0K 0 recipients
Compare payment profiles
SunMed Group Holdings, LLC
$60.3K 35 recipients
Compare payment profiles
Spirair, Inc.
$60.4K 219 recipients
Compare payment profiles
Clarius Mobile Health Corp.
$60.4K 27 recipients
Compare payment profiles
IZI Medical Products, LLC
$59.6K 15 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.